Reported about 5 hours ago
Danish pharmaceutical company Novo Nordisk has made an unsolicited offer of at least $6.5 billion to acquire obesity startup Metsera Inc., aiming to outbid a previously agreed deal with Pfizer. The offer, which includes an initial cash payment of $56.50 per share and potential milestone payments, is seen as superior by Metsera, which has four days to negotiate. Pfizer has criticized Novo's move as 'reckless' and an attempt to stifle competition. If successful, the acquisition could bolster Novo's position in the rapidly growing weight-loss medication market.
Source: YAHOO